Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Breast cancer is a leading cause of cancer death in women, with metastasis occurring in 20-30% of patients.
• Existing treatments like chemotherapy and targeted therapies often face challenges with therapeutic resistance, recurrence, and metastasis.
• Chimeric antigen receptor (CAR)-T cell therapy, a form of cancer immunotherapy, has shown potential but faces limitations in solid tumors.

Purpose of the Study:

• To discuss the prospects of CAR-T cell therapy for metastatic breast cancer.
• To review clinically relevant targets for CAR-T therapy in breast cancer.
• To propose solutions for challenges hindering CAR-T efficacy in solid tumors.

Main Methods:

• Review of current literature on CAR-T cell therapy in breast cancer.
• Identification and analysis of potential CAR-T targets (HER-2, C-MET, MSLN, CEA, MUC1, ROR1, EGFR).
• Exploration of strategies to overcome barriers such as tumor microenvironment and antigen heterogeneity.

Main Results:

• Several potential targets for CAR-T therapy in breast cancer have been identified at the clinical level.
• Challenges including off-target effects, heterogeneous antigen expression, and the immunosuppressive tumor microenvironment were analyzed.
• Potential strategies to enhance CAR-T cell therapy effectiveness were suggested.

Conclusions:

• CAR-T cell therapy holds promise for treating metastatic breast cancer.
• Addressing challenges related to the tumor microenvironment and antigen expression is crucial for therapeutic success.
• Further research and innovative approaches are needed to optimize CAR-T cell therapy for breast cancer patients.